Beam Therapeutics Inc.

NasdaqGS:BEAM Rapporto sulle azioni

Cap. di mercato: US$1.9b

Beam Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che il fatturato e gli utili di Beam Therapeutics diminuiscano rispettivamente di 11.9% e 11.9% all'anno. Si prevede che l'EPS diminuisca di 5% all'anno. Il rendimento del capitale proprio è previsto a -66.8% tra 3 anni.

Informazioni chiave

-11.9%

Tasso di crescita degli utili

-5.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.4%
Tasso di crescita dei ricavi-11.9%
Rendimento futuro del capitale proprio-66.8%
Copertura analitica

Good

Ultimo aggiornamento18 Nov 2024

Aggiornamenti recenti sulla crescita futura

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

Dec 20

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct 01

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:BEAM - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202658-445-355-32011
12/31/202555-417-347-31715
12/31/202450-388-349-33616
9/30/2024350-144-145-136N/A
6/30/2024353-143-153-137N/A
3/31/2024361-135-169-139N/A
12/31/2023378-133-183-149N/A
9/30/202382-314-392-353N/A
6/30/202380-327-380-338N/A
3/31/202377-316-353-306N/A
12/31/202261-289-2623N/A
9/30/202292-3153994N/A
6/30/202277-234123171N/A
3/31/202260-238148191N/A
12/31/202152-371-113-66N/A
9/30/20211-401-134-92N/A
6/30/20210-408-155-117N/A
3/31/20210-366-132-107N/A
12/31/20200-196-112-96N/A
9/30/20200-132-100-89N/A
6/30/20200-119-94-85N/A
3/31/20200-106-87-74N/A
12/31/20190-91-85-72N/A
9/30/20190-86-79-57N/A
6/30/20190-134-70-50N/A
3/31/2019N/A-124-57-42N/A
12/31/2018N/A-117-33-20N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che BEAM rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che BEAM rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che BEAM rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di BEAM diminuiranno nei prossimi 3 anni ( -11.9% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di BEAM diminuiranno nei prossimi 3 anni ( -11.9% all'anno).


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che BEAM non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita